Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy combo shows promise against tough esophageal cancer

NCT ID NCT04848753

Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before and after surgery helps people with a certain type of advanced esophageal cancer. About 663 participants will receive either toripalimab plus chemo or a placebo plus chemo. The goal is to see if the combination improves how long people live without the cancer coming back and increases the chance of complete tumor removal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

663 people

The number who actually took part.

Started

May 2021

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients must fulfill all of the following inclusion criteria to be eligible for enrollment in this study: 1. Histologically confirmed locally advanced (T1N1-3M0 or T2-3N0-3M0) squamous cell carcinoma of the thoracic esophagus (per the 8th Edition of UICC-TNM Classification); 2. No suspicious cervical lymph node metastasis on cervical contrast-enhanced CT; no systemic metastasis from radiological examination; 3. Expected to be achievable to conduct R0 resection. Patients must not enter this study if any of the following exclusion criteria is fulfilled: 1. Having malignant tumors other than esophageal carcinoma within 5 years prior to randomization; 2. Combined with other inoperable condition; 3. Previous serious allergy to chemotherapeutic agents (paclitaxel or cisplatin) or any monoclonal antibody; 4. Combined with other conditions unsuitable for participation in this study as judged by investigators. Other protocol defined Inclusion/exclusion criteria could apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Resectable locally advanced thoracic esophageal squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Resectable locally advanced thoracic esophageal squamous cell carcinoma

Contacts and locations

Locations

  • 3201 Hospital

    Hangzhou, China

  • Affiliated Tumor Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • Anhui Provincial Cancer Hospital

    Hefei, China

  • Anhui provincial hospital

    Hefei, Anhui, 230001, China

  • Anyang Cancer Hospital

    Anyang, Henan, China

  • Beijing Cancer Hospital

    Beijing, China

  • China-Japan Union hosptial of Jilin university

    Changchun, Jilin, 130031, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Henan provincial pepples hospital

    Zhengzhou, Henan, 450003, China

  • Heping Hospital Affiliated to changzhi Medical College

    Changzhi, China

  • Huai'an First People's Hospital

    Huai'an, China

  • Hubei Cancer Hospital

    Wuhan, China

  • Hunan provincial cancer hospital

    Changsha, Hunan, 410013, China

  • Hwa Mei Hospital,University of Chinese Academy of sciences

    Ningbo, Zhejiang, 315010, China

  • Jiangmen central Hospital

    Jiangmen, Guangdong, China

  • Jiangsu Cancer Hospital

    Nanjing, China

  • Liaoning cancer hospital& Institute

    Shenyang, China

  • Peking University Third Hospital

    Beijing, China

  • Renmin Hospital of Wuhan University

    Wuhan, China

  • Shantou University Cancer Hospital

    Shantou, China

  • Shanxi provincial cancer hosptial

    Taiyuan, Shanxi, 030013, China

  • Shengjing Hospital of China Medical University

    Shenyang, China

  • Shenzhen people's hosptial

    Shenzhen, Guangdong, 518040, China

  • Sichuan Cancer Hospital & Institute

    Chengdu, China

  • Taizhou hospital of zhejiang province

    Taizhou, Zhejiang, 317000, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, China

  • The Affiliated Hospital of jining Medical University

    Jining, China

  • The Affiliated Hospital of xuzhou Medical University

    Xuzhou, China

  • The Firest Affiliated Hospital of bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

  • The First Affiliated Hospital of nanchang University

    Nanchang, China

  • The First Affiliated Hospital of xinxiang Medical University

    Xinxiang, Henan, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hanzhou, China

  • The General Hospital of People's Liberation Army

    Beijing, China

  • The Second Hospital of anhui Medical University

    Hefei, Anhui, China

  • The first Hospital of china Medical University

    Shenyang, China

  • The first affilated hospital of zhengzhou university

    Zhengzhou, Henan, 450052, China

  • The first affiliated hospital of jinzhou medical university

    Jinzhou, Niaoning, 121001, China

  • The fourth hospital of hebei medical university

    Shijiazhuang, Hebei, 050019, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, China

  • Xinyang central Hospital

    Xinyang, China

  • Yantai yuhuangding Hospital

    Yantai, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Zhongshan Hospital Affiliated to Xiamen University

    Xiamen, China

  • Zhongshan Hospital Fudan University

    Shanghai, China

  • harbin medical university Cancer Hospital

    Harbin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.